

Receipt.

Patent
Attorney's Docket No. 032775-047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

In re Patent Application of

Donald Morris; et al.

Application No.: 09/847,355

Filed: May 3, 2001

For: VIRUS CLEARANCE OF
NEOPLASTIC CELLS FROM
MIXED CELLULAR
COMPOSITIONS

Group Art Unit: Unassigned

Examiner: Unassigned

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

Enclosed is a copy of the Official Filing Receipt marked in red to show that the Attorney Docket No. needs to be corrected. Please correct the Attorney Docket No. to read:

032775-047

Issuance of a corrected Official Filing Receipt is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:


Ping F. Hwung
Registration No. 44,164

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

Date: July 6, 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
SEP 12 2001
TECH CENTER 1600/2900
Page 1 of 4COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/847,355	05/03/2001	1633	400	032775-041	16	25	2

032775-047

CONFIRMATION NO. 6889

21839
BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA, VA 22313-1404

FILING RECEIPT



OC000000006244102

Date Mailed: 06/29/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Donald Morris, Calgary, CANADA;
Bradley Thompson, Calgary, CANADA;
Matthew Coffey, Calgary, CANADA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/201,990 05/03/2000
AND CLAIMS BENEFIT OF 60/205,389 05/19/2000
AND CLAIMS BENEFIT OF 60/268,054 02/13/2001
AND CLAIMS BENEFIT OF 60/276,782 03/16/2001

Foreign Applications

If Required, Foreign Filing License Granted 06/28/2001

Projected Publication Date: 11/08/2001

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Virus clearance of neoplastic cells from mixed cellular compositions


Preliminary Class

424

Data entry by : KANNO, MESERET

Team : OIPE

Date: 06/29/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2000

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 6889

SERIAL NUMBER 09/847,355	FILING DATE 05/03/2001 RULE	CLASS 424	GROUP ART UNIT 1636	ATTORNEY DOCKET NO. 032775-047
------------------------------------	---	---------------------	-------------------------------	--

APPLICANTS

Donald Morris, Calgary, CANADA;
 Bradley Thompson, Calgary, CANADA;
 Matthew Coffey, Calgary, CANADA;

**** CONTINUING DATA *******

THIS APPLN CLAIMS BENEFIT OF 60/201,990 05/03/2000
 AND CLAIMS BENEFIT OF 60/205,389 05/19/2000
 AND CLAIMS BENEFIT OF 60/268,054 02/13/2001
 AND CLAIMS BENEFIT OF 60/276,782 03/16/2001

**** FOREIGN APPLICATIONS *******

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 06/28/2001

**** SMALL ENTITY ****

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY CANADA	SHEETS DRAWING 16	TOTAL CLAIMS 25	INDEPENDENT CLAIMS 2
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS

21839

TITLE

Virus clearance of neoplastic cells from mixed cellular compositions

FILING FEE RECEIVED 800	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit